drugset
drugset / Trial / NCT06060067

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

NCT06060067 ↗

Phase 3 Completed 480 enrolled Takeda
RandomizedParallel-groupDouble-blindPrevention

Summary

The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months. Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will receive one dose of either the vaccine or placebo on Day 1 and the second dose of either the vaccine or placebo 3 months later. Up to 4 blood samples will be taken throughout the study. During the study, participants will visit their study clinic 6 times.

Timeline

Start
2024-03-29
Primary completion
2025-05-05
Completion
2025-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TDV Vaccine — —

Indications

No indication recorded.